Company news
Eupraxia Pharmaceuticals, Inc. news in 2022
Eupraxia Pharmaceuticals, Inc.'s news releases, calls and decks from 2022, newest first.
Eupraxia Pharmaceuticals Completes Patient Enrollment for its Phase 2 Trial in Knee Osteoarthritis
December 7, 2022
Eupraxia Pharmaceuticals Reports Third Quarter 2022 Financial Results
November 7, 2022
Eupraxia Pharmaceuticals Appoints Chief Business Officer
November 1, 2022
Eupraxia Pharmaceuticals Initiates Phase 2 Study in Eosinophilic Esophagitis
October 12, 2022
Eupraxia Pharmaceuticals Provides Update for Phase 2 Study in Knee Osteoarthritis for Lead Drug Candidate EP-104IAR
October 11, 2022
Eupraxia Pharmaceuticals Announces Expansion of Intellectual Property For EP-104IAR
September 26, 2022
Eupraxia Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference
September 7, 2022
Eupraxia Pharmaceuticals Reports Second Quarter 2022 Financial Results
August 12, 2022
Eupraxia Pharmaceuticals Recognized as Emerging Life Sciences Company of the Year by Life Sciences British Columbia
July 7, 2022
Eupraxia Pharmaceuticals to Present at BIO International Convention
June 8, 2022
Eupraxia Pharmaceuticals Reports First Quarter 2022 Financial Results
May 5, 2022
Eupraxia Pharmaceuticals Completes C$14.7 million Overnight Marketed Offering
April 20, 2022
Eupraxia Pharmaceuticals Inc. Reports Fourth Quarter and Full Year 2021 Financial Results
March 29, 2022
Eupraxia Pharmaceuticals to Present at BIO CEO & Investor Conference
February 9, 2022
Eupraxia Pharmaceuticals to Present at H.C. Wainwright BIOCONNECT Virtual Conference
January 6, 2022